Mucosal Vaccines and Challenge Research (MVAC)
The Mucosal Vaccines and Challenge (MVAC) team conducts investigational vaccine studies for ETEC, shigella cholera, campy, ebola, RSV and influenza as well as challenge studies. The team is led by Bloomberg School of Public Health assistant professor Dr. Kawsar Talaat.
Ebola virus disease (EVD) is a serious illness that is often fatal in humans. Ebola virus is initially transmitted to people through close contact with the bodily fluids of infected animals
ETEC (Enterotoxigenic E. coli)
Escherichia coli (E. coli) is a bacterium that lives in the intestines of humans and animals. Enterotoxigenic E. coli (ETEC) is the most common cause of diagnosed travelers’ diarrhea.
Campylobacter is transmitted through contact with infected feces, ingestion of raw or undercooked meat (mainly poultry) and contaminated drinking water.
Coronavirus disease 2019, better known as COVID-19, is a contagious respiratory illness that causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus can be spread from person to person and causes a variety of symptoms, which can appear 2-14 days after exposure.
Seasonal influenza (more commonly known as flu) is a contagious respiratory illness that primarily infects the nose and throat and is caused by three virus types in humans (influenza A, B, and C). Influenza infection sickens some people more than others depending on age and health status.
Support our Work
Help us continue the important work being done to find safe and effective vaccines for respiratory viruses!